Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Doribax. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Doripenem (sold as Doribax), first approved Oct 12, 2007, with 0 new uses approved and 0 published complete response letters.
FinibaxDrugs with a new additional pediatric dosage and with a new additional indication for the treatment of purulent meningitis. · Shionogi & Co., Ltd. · May 25, 2012
FinibaxDrugs with a new dosage that enables high-dose (1 g three times daily) use. · Shionogi & Co., Ltd. · Apr 22, 2011
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA